What Are the Main Canada–US Risks in an AI Transaction in 2026?

Direct Answer: Canada–US AI Deals Carry More Than Ordinary Deal Risk

A Canada–US artificial intelligence transaction can combine technology, national-security, privacy, intellectual-property, insurance, and capital-structure risks in one closing process. Depending on the transaction, parties may need to address Canadian foreign-investment review, US foreign investment restrictions, competition rules, securities filings, export controls, sanctions screening, data governance, cybersecurity, and the allocation of professional-liability exposure. The key phrase “Canada US AI transaction risks” is therefore too broad to describe the actual issue: the risk profile changes according to whether a company is acquiring another business, licensing its model, funding it, or building a joint data center. The highest-risk matters generally involve sensitive personal data, government customers, critical infrastructure, advanced semiconductor supply chains, biometric information, or an AI system with meaningful autonomous capabilities. A deal can close legally while still creating a costly dispute over who bears an E&O claim, an incident-response expense, a model-quality failure, or a post-closing regulatory penalty.

Also worth reading: How Do Founders and Investors Use AI for Transaction Due Diligence in 2026? · What Are the Basics of AI Agent Governance for Private Deal Networks? · How Do Founders Find Private AI Deal Flow Without Relying on Cold Outreach?

Neither government treats AI as an ordinary commodity. The United States can use national-security review to examine foreign access to sensitive technology, while Canada can consider strategic, security, and economic factors alongside investment character. The parties should not assume that incorporation in Delaware or a public stock-for-stock structure eliminates Canadian concerns. Likewise, Canadian “national champion” status is not a definitive legal category, and US ownership is not automatically prohibited. Instead, the relevant questions concern control, access rights, data, technology, customer relationships, and the transaction’s practical effect. A carefully structured transaction remains possible, but “possible” is not the same as unconditionally clearable. Companies should obtain jurisdiction-specific legal advice before signing exclusivity, exchanging sensitive technical data, or granting a foreign investor board or information rights.

How Canada and US Review Regimes Interact

Canadian and US regulators can become involved in parallel, and each regime addresses a different concern. Canadian national-security review generally considers whether a foreign investor’s acquisition of a Canadian business could harm Canada’s security, including through access to sensitive information, critical technology, critical infrastructure, or supply chains. A new investment by a SOE or a non-SOE investor can trigger analysis, while a later acquisition review may be required for a non-SOE investor acquiring control over a Canadian entity’s assets or voting interests above the applicable threshold. Because thresholds and implementation details can change, counsel should confirm the rules effective on the signing and closing dates rather than copying a deal memorandum written for 2023.

US CFIUS rules are comparatively well known. The $250,000 transaction-value exception is available only when the transaction qualifies for that exception; it does not create a general de minimis exemption. Otherwise, a covered transaction producing a covered financial interest may be reviewable, with a control investment generally involving at least 25% of a voting-interest class, subject to exceptions. Investments of at least 10% in certain cases can qualify, particularly where the investor obtains board representation, access to sensitive personal data, or substantive decision-making rights. A non-controlling 10% investment is not always exempt, especially for a US business with critical technology or sensitive personal data. Parties should also examine US export controls and sanctions, which can affect customers, distributors, model weights, training chips, and third-party cloud infrastructure after closing.

## Due Diligence: Finding the Actual Deal Risks

A useful diligence process starts by identifying the exact asset being transferred. Acquiring shares, intellectual property, contracts, cloud capacity, or a subsidiary produces different risks. A stock acquisition may leave historical liabilities with the acquired entity, while an asset purchase may require third-party consent, data-transfer analysis, employee transfers, and new licenses for software and model rights. AI diligence should go beyond a standard IP schedule: counsel should trace training data provenance, permission for web scraping, image and video rights, voice and biometric consent, open-source software obligations, model cards, evaluation records, and any restrictions imposed by data-center providers. A technically strong model can still be unmarketable if its training corpus lacks documented rights or if essential code depends on incompatible licenses.

Cybersecurity and data mapping are equally important. The parties should determine where personal information is collected, where it is stored, whether it is sold or licensed, which subprocessors can access it, and whether Canadian or US law treats it as sensitive. Cross-border service-provider contracts may require contractual flow-down provisions, deletion schedules, incident-notification deadlines, audit rights, and rules for government requests. A data map should distinguish production data from model-training data, and both from information retained in logs, embeddings, retrieval systems, and support tickets. Encryption in transit and at rest is a baseline control, not a complete response. Buyers should test privileged access, identity management, model supply-chain security, red-team performance, disaster recovery, and the process for reporting material incidents.

Financial and customer concentration add transaction risk even when the technology is sound. If one cloud provider, chip supplier, customer, or public-sector contract accounts for most revenue or capacity, a change of control may weaken the business. Diligence should quantify top-five customer concentration, remaining contract terms, change-of-control clauses, warranty obligations, and the share of compute spending needed to serve existing workloads. Companies should reconcile reported recurring revenue with contracted revenue because usage-based AI services can fall quickly. They should also examine deferred revenue, credits, service-level failures, data-center commitments, and capital expenditures. The goal is not to predict every operating outcome; it is to price a risk that may only become visible after closing.

Insurance, Liability, and Contract Allocation

AI errors create a distinct insurance gap. A traditional errors-and-omissions policy may cover professional services performed for a fee, but it may exclude the sale of an autonomous model, defective products, or contractual liability assumed in a technology transaction. A claim may involve incorrect advice, discrimination in a hiring or credit workflow, hallucinated output, infringement, privacy breach, security failure, or failure to meet a service-level agreement. The fact that a human approved an output does not automatically place the loss within a standard E&O policy. The wording, trigger, retroactive date, and exclusions of the actual policy matter more than its label.

Parties should compare the available response rather than assume that one policy settles the matter. Cyber and privacy insurance may respond to a security incident and first-party notification costs, but it may not cover consequential business interruption or contractual refunds. Technology E&O can cover certain design and service errors, but model-related exclusions or sublimits can limit recovery. Media, intellectual-property, crime, and cyber policies address narrower risks. Directors-and-officers coverage may protect individual leaders from some claims, not the company itself. Buyers may therefore need a layered program, additional limits, carefully drafted indemnity, escrow, insurance-backed representations, or seller obligations that survive closing. The premium, retention, and exclusions should be reviewed before the parties rely on insurance as protection.

## Practical Structure and Approval Strategy

The first practical step is to classify the transaction before selecting a structure. Parties should map the assets, data, contracts, government relationships, intellectual property, and financing terms, then identify the jurisdictions and regulators with authority. If only a minority financial investment is contemplated, removing board seats, observer rights, technical-data access, and veto rights may reduce—but not necessarily eliminate—regulatory sensitivity. If a strategic corporate buyer needs integration rights, a joint venture may offer more operational flexibility but can still produce national-security concerns. An asset sale can isolate unwanted liabilities, but it may weaken the narrative that the AI business is being protected as a coherent Canadian or US technology enterprise. The structure should serve both commercial and regulatory objectives rather than be chosen solely to avoid one filing.

The approval strategy should include red flags, information-room rules, government-contact protocols, and a mitigation plan. Parties can prepare a short ownership chart showing every intermediate investor, especially where sovereign wealth, pension, family-office, or foreign-corporate money participates. A US strategic investor’s ultimate funding source may be as important to reviewers as its direct shareholder. For AI companies, governments can ask whether training data, model weights, customer prompts, or security evaluations could be transferred to a parent or affiliated company. Contractual restrictions can help, but regulators may prefer formal conditions, supply-chain controls, or independent audits over promises in an ordinary commercial agreement. A transaction document should therefore distinguish pre-closing regulatory cooperation from the buyer’s post-closing operating rights.

Timing should be built around evidence and decision risk. Counsel should prepare a chronology, explain why the foreign investor is acquiring the business, describe who controls data and infrastructure, and show what sensitive capabilities remain unavailable outside the approved perimeter. A short, credible response to information requests is usually more useful than a highly technical submission that obscures the ownership facts. A long-stop date should be long enough to permit review but short enough to preserve financing alternatives. Termination fees, expense reimbursement, reverse-termination rights, and data-return obligations should be considered. If the parties expect regulatory conditions, they should not treat a filing acceptance as proof that the deal may close.

Common Mistakes That Can Delay or Defeat a Deal

One common error is treating a private AI deal as ordinary M&A because no public announcement is required. Private transactions can still trigger foreign-investment, competition, contractual, export-control, and data-protection consequences. Another error is assuming that “AI” alone makes a company a national-security asset. Regulators focus on concrete capabilities and access. A small customer-service assistant with no sensitive data may present a different case from a system that controls power-grid optimization, identifies people from images, or supplies a defense contractor. Blanket “AI risk” labels can produce unnecessary legal cost and delay, just as vague claims of “no sensitive data” can produce a request for detailed evidence.

Parties also err by exchanging sensitive materials too early. Technical architecture, model evaluations, customer names, security incidents, and data-flow diagrams can reveal commercially valuable and regulated information before the transaction is approved. Diligence access should be staged, with clean-team arrangements, redaction, watermarking, and limits on copying. Confidentiality provisions help, but they do not automatically bind a regulator investigating the transaction. A separate error is relying on generic reps-and-warranties language for AI facts. Representations concerning training-data rights, model ownership, output testing, privacy compliance, and cybersecurity claims may require detailed disclosure schedules and tailored survival periods. The purchase agreement should also distinguish known model limitations from representations that would convert an ordinary technical characteristic into a breach.

Timing and pricing mistakes are common. Waiting until the last week before the long-stop date to launch a regulatory review can leave no room for a second request, a mitigation negotiation, or a prohibition. Pricing every AI-specific risk as a percentage of enterprise value is also unsound. The relevant number may be a contract cap, insurance limit, data-center commitment, or a single customer’s remaining revenue. Parties should use scenario analysis: a privacy incident, a 30-day compute interruption, a lost top customer, and a model-licensing claim have different probabilities and consequences. Those scenarios should inform the purchase price, escrow, indemnity, retention, and financing conditions rather than becoming a single unsupported “AI discount.”

When to Act and What It May Cost

A company should begin regulatory and insurance analysis before it circulates a teaser, gives a buyer access to sensitive data, or grants exclusivity. The useful deadline is not simply “before signing”; it is before commitments become difficult to unwind and before the parties create a public expectation of a closing. Early work can include a two-week issue-spotting exercise, a data and IP request list, and a preliminary insurance-market inquiry. That is not the same as a full transaction review. A formal diligence sprint may take four to eight weeks, while regulatory engagement, mitigation negotiations, and closing conditions can extend the process to several months or longer. Complex sovereign investments, defense-linked customers, or data-center projects often require more time than a straightforward corporate acquisition.

Costs depend on scope and jurisdiction. A limited ownership-and-sanctions screen may cost a few thousand dollars, while a high-level CFIUS, Canada, privacy, and data-security assessment can run into the tens of thousands. Full transaction documents, specialist AI diligence, insurance advice, and a formal regulatory filing can move the total into the low or mid six figures; heavily negotiated national-security mitigation may cost more. Cyber and technology E&O premiums vary by revenue, industry, data sensitivity, controls, claims history, limits, and exclusions. A small company should not quote a universal premium. Obtain at least two market indications, specify the limits and retention, and ask what scenarios the insurer expressly excludes. A policy is inexpensive only if it responds to the actual AI risk and remains available after the deal changes the business.

For the Mercer Club NYC audience, the relevant opportunity is disciplined deal preparation, not a promise of guaranteed regulatory clearance or investor interest. Founders and operators can use a private AI deal-flow network to identify comparable transactions, test valuation assumptions, and connect with US and Canadian capital without publishing confidential data. Before a counterpart receives a teaser, the founder should know which rights are actually being sold, whether the data can be transferred, and which regulatory or insurance questions are unresolved. A credible process starts with a concise data room, a source-of-funds explanation, a cap table, customer concentration analysis, model provenance record, and a list of required approvals. The best deal is not merely the highest offer; it is the offer that can survive diligence, financing, integration, and a regulatory consent process.

A Transaction Readiness Framework

Readiness should be evaluated across commercial, regulatory, technical, and financial evidence. Commercially, the seller should be able to explain recurring demand, customer concentration, contract portability, and switching costs. Technically, it should be able to show model ownership, training-data rights, cloud commitments, security testing, and incident history. Financially, the buyer should understand the difference between reported ARR, contracted usage, gross margin after inference costs, and cash burn. Regulators should be able to trace ownership and understand which data, technology, and governance rights change hands. Insurers should understand the product, the customers, the controls, and the claims history. If one of those groups receives a different story, the closing risk rises.

A useful final review asks what could cause a deal to fail, what could make it unprofitable after closing, and who can absorb each loss. The answers may include a prohibited investment, a required mitigation, loss of a government contract, an unavailable chip supply, a data-transfer restriction, a service-level failure, or an uncovered model claim. The analysis should record assumptions and dates rather than use vague conclusions. It should also identify the person authorized to communicate with Canadian and US authorities, the customer information that may be disclosed, and the procedure for responding to a government request. This is especially important where the seller is incorporated in one country, the IP is registered in another, the data center is in a third, and the investor has still another home jurisdiction.

No general risk score can replace legal advice, but a structured framework can prevent avoidable errors. Companies should separate mandatory approvals from optional review, regulatory conditions from ordinary commercial protections, and insured losses from seller-credit exposure. They should revisit the analysis if the structure changes after negotiation—for example, if a planned 9% investment gains board representation, or if a model-serving contract becomes part of the acquired assets. As of September 27, 2026, counsel should also confirm current filing thresholds and any changes to Canadian implementation, US CFIUS rules, export controls, or competition thresholds. The most reliable advice is current, transaction-specific, and prepared for the exact rights the parties intend to grant.